BioMark Diagnostics Inc. (BUX) has entered into a collaborative research and development agreement with Phytronix Technologies.
This agreement will advance BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology.
While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Québec City to accelerate its assays' commercialization, the Québec-based Phytronix will bring its experience in high-throughput analysis, automated sample preparation and assay development to this collaboration.
"The group intends to widen the scope of the partnership to include the development of an ultra-high-throughput technique, using the LDTD-based Luxon-MS/MS system, for lung cancer screening applications and establish new standards to further increase the sensitivity of the assay," says BioMark CEO Rashid Bux.
"Ultimately, the increased sensitivity can help determine better sub-types of lung cancer as well as increasing the robustness and the speed of the assay," added Bux.
Thanks to the expertise it has developed for more than 20 years, Phytronix will support BioMark's team in setting up state-of-the-art clinical lab services in Québec and perform technical training on the Luxon-MS/MS system.
Phytronix's technical capabilities in instrumentation, support, and service are an important part of the clinical laboratory infrastructure BioMark Diagnostic Solutions is building in Québec City.
Both companies intend to demonstrate the technology's uniqueness by showcasing it later in 2021 through a sponsored research program.
"In addition, Phytronix's installed base within CLIA-certified labs in the U.S. could be an important driver for the adoption of BioMark's early lung cancer screening assay across North America and other global markets," concluded Bux.
Phytronix Technologies Inc. is a privately-owned company based in Québec City, Canada, founded in 2000.
Phytronix invented and patented the Laser Diode Thermal Desorption (LDTD) technology for mass spectrometry.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions that can help detect, monitor, and assess treatment for cancer early and cost-effectively.
BioMark Diagnostics (BUX) is up 2.38 per cent and is trading at C$0.22 at 12:33 pm EST.